The Cancer Center Director has the responsibility and authority to set priorities and to develop new programs for the Cancer Center. Faculty and senior leadership are the primary drivers in developing the focus of new research areas. External consultants and seminar speakers provide new perspectives on emerging areas of research and provide useful advice for possible future research directions. The Cancer Center leadership and several internal advisory groups serve to develop a specific set of goals from identified opportunities and available resources. The External Scientific Advisory Committee (EXSAC) meets each spring to review existing programs and proposed recruitment and scientific targets that have been developed by the senior leadership and faculty. These discussions inform the recruitment targets and planning efforts that begin each fall. Once new research goals are set, faculty are encouraged to pursue and support these goals through incentives that include pilot project funding, research instrumentation purchases, development of shared facilities, and recruitment of new faculty who are potential collaborators. Identification of shared facility and common equipment needs originates with the investigators and their laboratory staff, and is integrated at the level of the Internal Steering and Shared Resources Committees. Program members serving on recruitment committees identify and recommend the selection of new faculty, who bring to the Cancer Center new research areas, technologies, and opportunities for collaboration. The main internal advisory bodies include: i) the Cancer Center Executive Committee, ii) the Internal Steering Committee, iii) the Membership Committee and iv) the Shared Resources Committee. The External Scientific Advisory Committee (EXSAC) currently has 10 members representative of a broad spectrum of cancer research. Funding in the amount of $10,000 is requested for the annual meeting of the EXSAC;$5,000 is requested for the annual Cancer Center member retreat, and $6,000 is requested for planning and evaluation meetings for the Scientific Program groups.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA010815-44
Application #
8461256
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
44
Fiscal Year
2013
Total Cost
$33,484
Indirect Cost
$14,021
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Saglam, Ozlen; Conejo-Garcia, Jose (2018) PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. Integr Cancer Sci Ther 5:
Liu, Shujing; Zhang, Gao; Guo, Jianping et al. (2018) Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 9:5426
Duperret, Elizabeth K; Trautz, Aspen; Stoltz, Regina et al. (2018) Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo. Cancer Res 78:6363-6370
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Kugel 3rd, Curtis H; Douglass, Stephen M; Webster, Marie R et al. (2018) Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24:5347-5356
Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072
Bhattacharjee, Souvik; Coppens, Isabelle; Mbengue, Alassane et al. (2018) Remodeling of the malaria parasite and host human red cell by vesicle amplification that induces artemisinin resistance. Blood 131:1234-1247
Fukumoto, Takeshi; Park, Pyoung Hwa; Wu, Shuai et al. (2018) Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Rep 22:3393-3400
Thangavel, Chellappagounder; Boopathi, Ettickan; Liu, Yi et al. (2018) Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer. Clin Cancer Res 24:1402-1414

Showing the most recent 10 out of 741 publications